Preliminary results from a phase I expansion study of ZG005, a bispecific antibody targeting TIGIT and PD-1, as monotherapy in patients with advanced solid tumors

被引：0
|
作者：
Qin, Shukui
Cheng, Ying
Wang, Qiming
Cheng, Shuxia
Chai, Xiaoli
Wu, Lihua
Yu, Yan
Shi, Jianhua
Li, Xiumin
Fan, Lianlian
Xia, Jin
Huang, Yisheng
Ji, Yinghua
Zhuang, Zhixiang
Yang, Lei
Jiang, Ou
Zheng, Qinhong
Liao, Sihai
Yi, Shanyong
Ye, Huangyang
机构：
[1] Nanjing Chinese Med Univ, Jinling Hosp, Canc Ctr, Nanjing, Peoples R China
[2] Jilin Canc Hosp, Changchun, Peoples R China
[3] Zhengzhou Univ, Affiliated Canc Hosp, Zhengzhou, Peoples R China
[4] Henan Canc Hosp, Zhengzhou, Peoples R China
[5] ChangSha TaiHe Hosp, Changsha, Peoples R China
[6] Shulan (Hangzhou) Hosp, Hangzhou, Peoples R China
[7] Harbin Med Univ, Internal Med Dept 6, Canc Hosp, Harbin, Peoples R China
[8] Linyi Canc Hosp, Linyi, Shandong, Peoples R China
[9] Linyi Canc Hosp, Dept Gynecol Oncol, Linyi, Shandong, Peoples R China
[10] Deyang Peoples Hosp, Deyang, Peoples R China
[11] Anyang Tumor Hosp, Anyang, Henan, Peoples R China
[12] Maoming Peoples Hosp, Dept Oncol, Maoming, Peoples R China
[13] Xinxiang Med Univ, Affiliated Hosp 1, Xinxiang, Henan, Peoples R China
[14] Soochow Univ, Dept Oncol, Affiliated Hosp 2, Suzhou, Peoples R China
[15] Nantong Canc Hosp, Nantong, Peoples R China
[16] Second Peoples Hosp Neijiang, Neijiang, Peoples R China
[17] Peoples Hosp Quzhou, Quzhou, Peoples R China
[18] Guangdong Med Univ, Affiliated Hosp, Zhanjiang, Peoples R China
[19] Zhengzhou Cent Hosp, Dept Med Oncol, Zhengzhou, Peoples R China
[20] Xiamen Univ, Affiliated Hosp 1, Xiamen, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2611
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A phase Ia/b study of TIM-3/PD-L1 bispecific antibody in patients with advanced solid tumors.
    Hellmann, Matthew David
    Shimizu, Toshio
    Doi, Toshihiko
    Hodi, F. Stephen
    Rottey, Sylvie
    Aftimos, Philippe Georges
    Liu, Zhuqing Tina
    de Mendizabal, Nieves Velez
    Szpurka, Anna M.
    Piao, Yongzhe
    Vangerow, Burkhard
    Gandhi, Leena
    Leow, Ching Ching
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [32] A phase 1, dose escalation/dose-expansion study of QLF31907, a bispecific antibody (BsAb) targeting PD-L1 and 4-1BB, in patients with advanced solid tumors and lymphoma
    Lin, Tongyu
    Liu, Bin
    Pu, Xingxiang
    Wu, Lin
    Du, Xiaobo
    Mo, Ning
    Song, Zhengbo
    Zhou, Liwei
    Duan, Xianlin
    Zhu, Yanan
    Kang, Xiaoyan
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [33] First-in-class PD-1/IL-2 bispecific antibody fusion protein IBI363 in patients with other solid tumors: Safety and efficacy results from a phase I study.
    Bai, Xueli
    Xu, Qin
    Liang, Xinjun
    Chu, Qian
    Zhang, Xiaochen
    Chen, Yiwen
    Xu, Nong
    Fang, Weijia
    Shan, Jianzhen
    Jiang, Weiqin
    Zhou, Jianya
    Zheng, Yu-Long
    Long, Sixiang
    Chen, Haonan
    Zhao, Li
    Wang, Hongli
    Sun, Jiya
    Sun, Xing
    Zhou, Hui
    Liang, Tingbo
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [34] Phase I study of the anti-TIGIT antibody tiragolumab in combination with atezolizumab in Japanese patients with advanced or metastatic solid tumors
    Yamamoto, Noboru
    Koyama, Takafumi
    Sato, Jun
    Yoshida, Tatsuya
    Sudo, Kazuki
    Iwasa, Satoru
    Kondo, Shunsuke
    Yonemori, Kan
    Kawasaki, Atsuko
    Satake, Kyoko
    Shibata, Shoyo
    Shimizu, Toshio
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2024, 94 (01) : 109 - 115
  • [35] SI-B003 (PD-1/CTLA-4) in patients with advanced solid tumors: A phase I study
    Wang, Yakun
    Li, Yongsheng
    Liu, Jiyan
    Luo, Su-xia
    Li, Qi
    Zou, Wen
    Wang, Zhaoxiang
    Peng, Yujia
    Xiao, Sa
    Wang, Hongwei
    Zhu, Hai
    Olivo, Martin Sebastian
    Zhu, Yi
    Shen, Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [36] Preliminary results of a phase I dose escalation study of IMM2510, a PD-L1 and VEGF bispecific fusion protein, in patients with advanced tumors
    Cheng, Xiangdong
    Song, Zhengbo
    Zhang, Jian
    Jin, Jianan
    Gao, Shuiping
    Liu, Rujiao
    Sun, Yuping
    Zhang, Yan
    Gao, Shegan
    Jia, Ruinuo
    Jing, Deqiang
    Xu, Yu
    Zheng, Lina
    Zhao, Xiwen
    Li, Wei
    Lu, Qiying
    Tian, Wenzhi
    Hu, Xichun
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [37] First-in- class PD-1/IL-2 bispecific antibody fusion protein IBI363 in patients (pts) with advanced solid tumors: First-in-human phase I study
    Bai, X.
    Chen, Y.
    Chen, Y.
    Liang, X.
    Wang, H.
    Sun, Y.
    Chu, Q.
    Pan, Y.
    Cui, J.
    Fang, J.
    Zhang, W.
    Xu, Q.
    Zhang, J.
    Liu, X.
    Dai, G.
    Kang, L.
    Li, N.
    Fang, M.
    Zhou, H.
    Liang, T.
    ANNALS OF ONCOLOGY, 2024, 35 (07) : 681 - 682
  • [38] Phase I study of MK-3475 (anti-PD-1 monoclonal antibody) in patients with advanced solid tumors
    Patnaik, Amita
    Kang, Soonmo Peter
    Tolcher, Anthony W.
    Rasco, Drew Warren
    Papadopoulos, Kyriakos P.
    Beeram, Muralidhar
    Drengler, Ronald
    Chen, Cong
    Smith, Lon
    Perez, Crystal
    Gergich, Kevin
    Lehnert, Manfred
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [39] A phase I study of MEDI4736, NNT-PD-L1 antibody in patients with advanced solid tumors
    Zielinski, Christoph C.
    TRANSLATIONAL LUNG CANCER RESEARCH, 2014, 3 (06) : 406 - 407
  • [40] Phase I study of the anti-PD-1 antibody SHR-1210 in patients with advanced solid tumors.
    Huang, Jing
    Mo, Hongnan
    Wu, Dawei
    Chen, Xuelian
    Ma, Lanying
    Lan, Bo
    Qu, Dong
    Yang, Qing
    Xu, Binghe
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345